Sanofi decides to keep Cepia biz

This article was originally published here

SanofiSanofi (NYSE:SNY) has decided to keep its Cepia chemical unit, a spokesperson for the company said on Friday.

The Cepia division, which deals with what Sanofi calls ‘third party activities’ such as the supply and production of active pharmaceutical ingredients, was previously being considered for sale in a deal that could have been worth up to $1.1 billion (EU €1 billion).

Read the whole story on our sister site, Drug Delivery Business

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply